Get the Stockscreener App
73.17
2.49%
1.78
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $73.17, with a volume of 1.69M.
It is up +2.49% in the last 24 hours and up +6.48% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$71.39
Open:
$71.25
24h Volume:
1.69M
Relative Volume:
1.89
Market Cap:
$11.63B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
48.14
EPS:
1.52
Net Cash Flow:
$245.03M
1W Performance:
-3.33%
1M Performance:
+6.48%
6M Performance:
-1.82%
1Y Performance:
-3.55%
1-Day Range:
$71.25
$74.27
1-Week Range:
$69.48
$77.62
52-Week Range:
$61.16
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
73.17 | 11.63B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - Yahoo Finance
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Bio-Techne partners with Waters for biotherapeutic tech - Investing.com
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT - Yahoo Finance
ScaleReady awards a G-Rex® Grant to Moonlight Bio - Yahoo Finance
Lord Abbett & CO. LLC Has $23.73 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Short Interest Up 15.6% in November - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Toronto Dominion Bank - MarketBeat
Oddo BHF Asset Management Sas Invests $1.19 Million in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Barclays PLC Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain? - MSN
National Bank of Canada FI Purchases 37,181 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY - Quantisnow
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, Bio-Techne Lag - Barron's
West Sac-based GeminiBio acquires a large serum producer's brands, customers - The Business Journals
BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY - Yahoo Finance
Wellington Management Group LLP Sells 147,797 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
State Street Corp Grows Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Tenere Capital LLC Grows Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Worldquant Millennium Advisors LLC Buys 22,185 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Polar Asset Management Partners Inc. Lowers Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Janus Henderson Group PLC Lowers Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Can Mixed Financials Have A Negative Impact on Bio-Techne Corporation's 's (NASDAQ:TECH) Current Price Momentum? - Yahoo Finance
PEAK6 Investments LLC Invests $698,000 in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Exosome Research Products Industry Research Report 2023-2030, Featuring AMS, Bio-Techne, Lonza, Miltenyi Biotech, Nanosomix, Norgen Biotek, NX Pharmagen, Qiagen, SBI, Thermo Fisher Scientific - Yahoo Finance
Bio-Techne Co. (NASDAQ:TECH) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Why Bio-Techne Corp (TECH) Is Set to Outperform the Market: Insi - GuruFocus.com
Bamco Inc. NY Lowers Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Should You Continue to Retain Bio-Techne Stock in Your Portfolio? - Yahoo Finance
BNP Paribas Financial Markets Sells 52,235 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
The Manufacturers Life Insurance Company Has $15.93 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
American Capital Management Inc. Has $89.07 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Fred Alger Management LLC Has $52.07 Million Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Analysts Set Bio-Techne Co. (NASDAQ:TECH) Price Target at $81.78 - MarketBeat
TECH (Bio-Techne) 3-Year Revenue Growth Rate : 7.80% (As of Sep. 2024) - GuruFocus.com
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Dai ichi Life Insurance Company Ltd Has $423,000 Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More - Yahoo Finance
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE - Quantisnow
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE – Company Announcement - Financial Times
Charles Schwab Investment Management Inc. Has $113.02 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Position Raised by Cerity Partners LLC - MarketBeat
Bio-Techne (TECH) Shares Cross Above 200 DMA - Nasdaq
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Massachusetts Financial Services Co. MA Cuts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Mutual of America Capital Management LLC Purchases 8,852 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (MEX:TECH) Dividend Payout Ratio : 0.19 (As of Sep. 2024) - GuruFocus.com
Bio-Techne (MEX:TECH) Debt-to-Equity : 0.19 (As of Sep. 2024) - GuruFocus.com
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb Or Sink? - Barchart
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb or Sink? - Inkl
Bio-Techne (BSP:T1CH34) Enterprise Value : R$70,339 Mil (As of Nov. 21, 2024) - GuruFocus.com
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hippel James | CFO |
Nov 01 '24 |
Option Exercise |
0.00 |
13,159 |
0 |
113,085 |
| HIGGINS JOHN L | Director |
Sep 12 '24 |
Option Exercise |
22.95 |
6,000 |
137,700 |
48,608 |
| Kelderman Kim | Chief Executive Officer |
Aug 29 '24 |
Option Exercise |
66.97 |
1,492 |
99,919 |
41,434 |
| Bohnen Shane | SVP - General Counsel |
Aug 15 '24 |
Option Exercise |
0.00 |
49 |
0 |
1,696 |
| BAUMGARTNER ROBERT V | Director |
Aug 08 '24 |
Option Exercise |
22.95 |
16,000 |
367,200 |
59,401 |
| BAUMGARTNER ROBERT V | Director |
Aug 08 '24 |
Sale |
72.10 |
16,000 |
1,153,664 |
43,401 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):